Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Leo Miller

Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?

For weight loss drug leaders, the last two weeks have been nothing short of disastrous for shares.

Industry pioneer Novo Nordisk A/S (NYSE: NVO) saw its stock drop nearly 22% on July 29 after lowering its full-year guidance. Then, on Aug. 7, Eli Lilly (NYSE: LLY) shares fell approximately 14%.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.